Joint with: Neuroinflammation in Health and Disease
Neurodegeneration: From Neurocentric to System-Wide Perspectives
Jun 22–25, 2026 | Fairmont Chateau Whistler, Whistler, BC, Canada
Scientific Organizers:
Julia TCW, Christian Haass and Emma Mead
In Person
On Demand
Jun 22–25, 2026 | Fairmont Chateau Whistler, Whistler, BC, Canada
Scientific Organizers:
Julia TCW, Christian Haass and Emma Mead
Available Formats:
Supported by the Directors' Fund
In Person
On Demand
Available Formats: = In Person = On Demand
Monday, June 22, 2026
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Tuesday, June 23, 2026
Breakfast
7:00–8:00 AM
Welcome and Keynote Session (Joint)
8:00–9:00 AM
Randall Bateman †, Washington University School of Medicine
Amyloid, tau, Neurodegeneration, Inflammation in AD
Amyloid, tau, Neurodegeneration, Inflammation in AD
Astrid Iversen †, University of Oxford
Genomic Risk for Neuroinflammation
Genomic Risk for Neuroinflammation
Integrating Degeneration and Inflammation (Joint)
9:00–11:15 AM
Malu G. Tansey, University of Florida
Role of Central-Peripheral Neuroimmune Cross-Talk in Neurodegeneration
Role of Central-Peripheral Neuroimmune Cross-Talk in Neurodegeneration
Christian Haass, Ludwig-Maximilians University Munich
Modulation of Microglial Function
Modulation of Microglial Function
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
Poster Setup
11:15–1:00 PM
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Panel Discussion: From Research to Clinical Practice
2:30–4:30 PM
Coffee Available
4:30–5:00 PM
Neurodegenerative Disease Diagnostic to Therapeutics
5:00–7:00 PM
Rahul Atmaramani †, insitro
Machine Learning to Identify Disease Relevant Phenotypes in ALS iPSC Cultures
Machine Learning to Identify Disease Relevant Phenotypes in ALS iPSC Cultures
Erik J. Sontheimer †, University of Massachusetts Medical School
RNA Therapeutics
RNA Therapeutics
Henne Holstege †, Amsterdam UMC
Biomarker for Centenarians
Biomarker for Centenarians
Speaker to be Announced
PET Tracer (Amyloid, a-Synuclein, Microglia Activity Markers) or Others
PET Tracer (Amyloid, a-Synuclein, Microglia Activity Markers) or Others
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, June 24, 2026
Breakfast
7:00–8:00 AM
Disease Overarching Mechanisms of Neurodegenerative Diseases
8:00–11:00 AM
Julia TCW, Boston University
Lipophagic Defect by APOE4 in AD Glia
Lipophagic Defect by APOE4 in AD Glia
Justin Ichida †, BioMarin Pharmaceuticals, Inc.
Rare Diseases Mechanism and Drug Discovery
Rare Diseases Mechanism and Drug Discovery
Aaron D. Gitler †, Stanford University School of Medicine
Single Cell Mechanisms of Neurodegeneration
Single Cell Mechanisms of Neurodegeneration
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
Poster Setup
11:00–1:00 PM
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Myeloid-Based Disease Mechanisms for Neurodegenerative Diseases
5:00–7:00 PM
Donna M. Wilcock †, Indiana University School of Medicine
Therapeutic Trem2 Activation Ameliorates Amyloid-beta Deposition and Improves Cognition in the 5XFAD Model of Amyloid Deposition
Therapeutic Trem2 Activation Ameliorates Amyloid-beta Deposition and Improves Cognition in the 5XFAD Model of Amyloid Deposition
Zhiqiang An †, The University of Texas Health Science Center at Houston
A Tetravalent TREM2 Agonist
A Tetravalent TREM2 Agonist
Marco Colonna †, Washington University School of Medicine
Microglial Neurodegeneration Mechanisms
Microglial Neurodegeneration Mechanisms
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Thursday, June 25, 2026
Breakfast
7:00–8:00 AM
Drug Delivery (Joint)
8:00–11:00 AM
Fiona C. Elwood †, Janssen R&D
Developing Drugs for CNS Disorders: Considerations for Therapies That Cross the BBB
Developing Drugs for CNS Disorders: Considerations for Therapies That Cross the BBB
Kate Monroe †, Denali Therapeutics
Drug Delivery Targeting Microglia and Neurodegeneration
Drug Delivery Targeting Microglia and Neurodegeneration
Susan Alford †, Novo Nordisk
GLP1-ra - (Target Glucose Metabolism) (Glucagon like Peptide) Alters Immune Metabolism (Mechanism and Trials)
GLP1-ra - (Target Glucose Metabolism) (Glucagon like Peptide) Alters Immune Metabolism (Mechanism and Trials)
Michele Bronson †, Ventus Therapeutics
Targeting NLRP3 for Neuroinflammation and Neurodegeneration (Mechanism and Trials)
Targeting NLRP3 for Neuroinflammation and Neurodegeneration (Mechanism and Trials)
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Symposia Spotlight: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
Target-Based Therapeutics
5:00–6:45 PM
Emma Mead, Oxford Drug Discovery Institute
USP11 Inhibitors and tau Proteostasis
USP11 Inhibitors and tau Proteostasis
Haiyan Peng †, Alnylam, Inc.
The Application of RNAi Therapeutics in Neurodegenerative Diseases
The Application of RNAi Therapeutics in Neurodegenerative Diseases
Marcos Costa †, F. Hoffmann-La Roche Ltd
Correcting RNA Mis-Splicing in TDP-43 Proteinopathy
Correcting RNA Mis-Splicing in TDP-43 Proteinopathy
Short Talk(s) Chosen from Abstracts
Closing Keynote Address
6:45–7:30 PM
Dennis J. Selkoe †, Harvard Medical School
A Century of Alzheimer’s Research – Did We Finally Reach Our Goal?
A Century of Alzheimer’s Research – Did We Finally Reach Our Goal?
Meeting Wrap-Up: Outcomes and Future Directions
7:30–7:45 PM
Social Hour with Lite Bites
7:45–8:45 PM
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Friday, June 26, 2026
Departure
12:00–11:59 PM
Subscribe for Updates